Prominent publications by Michel Dominique Ferrari

KOL Index score: 20419

BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine. We assessed its efficacy and tolerability in patients with episodic migraine in whom previous treatment with two-to-four migraine preventives had been unsuccessful.

METHODS: LIBERTY was a 12-week, double-blind, placebo-controlled randomised study at 59 sites in 16 countries. ...

Also Ranks for: Episodic Migraine |  erenumab patients |  efficacy tolerability |  preventive treatments |  greater reduction
KOL Index score: 18213

BACKGROUND: Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP antibody, in patients with migraine who had previously not responded to two to four classes of migraine preventive medications.

METHODS: The randomised, double-blind, placebo-controlled, parallel-group, phase 3b FOCUS trial was done at 104 sites (including ...

Also Ranks for: Migraine Prevention |  placebo fremanezumab |  12 weeks |  baseline monthly average |  preventive treatment
KOL Index score: 17552

CONTEXT: Clinical series have suggested an increased prevalence of cerebral infarction and white matter lesions (WMLs) in migraine patients. It is not known whether these lesions are prevalent in the general migraine population.

OBJECTIVES: To compare the prevalence of brain infarcts and WMLs in migraine cases and controls from the general population and to identify migraine characteristics associated with these lesions.

DESIGN: Cross-sectional, prevalence study of population-based ...

Also Ranks for: Brain Lesions |  migraine controls |  aura patients |  attack frequency |  increased prevalence
KOL Index score: 15632

BACKGROUND: Calcitonin gene-related peptide (CGRP) probably has a role in migraine pathophysiology, and antagonism of its receptors might provide treatment without the vasoconstrictor effects of triptans. We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor.

METHODS: In a randomised, parallel-treatment, placebo-controlled, double-blind, trial at 81 sites in the Europe and the USA, adults with migraine diagnosed by ...

Also Ranks for: Peptide Receptor |  calcitonin gene |  efficacy telcagepant |  zolmitriptan placebo |  pain freedom
KOL Index score: 15302

OBJECTIVE: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures.

METHODS: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate ...

Also Ranks for: 2 Hours |  patients sumatriptan |  oral rizatriptan |  naratriptan zolmitriptan |  pain free
KOL Index score: 14585

BACKGROUND: The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon be clinically available, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis; this will provide a foundation for using triptans in clinical practice.

METHOD: We asked pharmaceutical companies and the principal investigators of ...

Also Ranks for: Oral Triptans |  53 trials |  serotonin 5 |  acute migraine treatment |  efficacy consistency
KOL Index score: 14583

The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs. Soon, seven different triptans will be clinically available at 13 different oral doses, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis. We wished to provide an evidence-based foundation for using triptans in clinical practice, and to review the methodological issues surrounding triptan trials. We asked pharmaceutical ...

Also Ranks for: Oral Triptans |  efficacy consistency |  migraine data |  tolerability sumatriptan |  53 trials
KOL Index score: 13692

Sudden unexpected death in epilepsy (SUDEP) is a fatal complication of epilepsy in which brainstem spreading depolarization may play a pivotal role, as suggested by animal studies. However, patiotemporal details of spreading depolarization occurring in relation to fatal seizures have not been investigated. In addition, little is known about behavioural and neurophysiological features that may discriminate spontaneous fatal from non-fatal seizures. Transgenic mice carrying the missense ...

Also Ranks for: Fatal Seizures |  spreading depolarization |  cacna1as218l mice |  epilepsy sudep |  seizure induced
KOL Index score: 13607

Rizatriptan (MK-462) is a potent 5HTID receptor agonist. This multicenter, double-blind, placebo-controlled, outpatient study investigated the clinical efficacy, safety, and tolerability of rizatriptan (2.5, 5, and 10 mg) as a function of dose for acute migraine. Patients with moderate or severe migraine (n = 417) were treated with placebo (n = 67), rizatriptan 2.5 mg (n = 75), 5 mg (n = 130), or rizatriptan 10 mg (n = 145). Headache severity, functional disability, and migraine symptoms ...

Also Ranks for: Patients Rizatriptan |  acute treatment |  5 10 |  pain relief |  adverse experiences
KOL Index score: 13600

OBJECTIVE: To assess the involvement of the 19p13 familial hemiplegic migraine (FHM) locus in migraine with and without aura.

BACKGROUND: Migraine with and without aura are likely to be polygenetic multifactorial disorders. FHM is a rare dominantly inherited type of migraine with aura. In about 50% of families, FHM is caused by mutations in the P/Q-type calcium channel alpha(1A)-subunit (CACNA1A) gene on chromosome 19p13. The CACNA1A gene is thus a good candidate gene for "nonhemiplegic" ...

Also Ranks for: Migraine Aura |  cacna1a gene |  lod score |  19p13 locus |  calcium channels
KOL Index score: 13222

Trivial head trauma may be complicated by severe, sometimes even fatal, cerebral edema and coma occurring after a lucid interval ("delayed cerebral edema"). Attacks of familial hemiplegic migraine (FHM) can be triggered by minor head trauma and are sometimes accompanied by coma. Mutations in the CACNA1A calcium channel subunit gene on chromosome 19 are associated with a wide spectrum of mutation-specific episodic and chronic neurological disorders, including FHM with or without coma. We ...

Also Ranks for: Minor Head Trauma |  delayed cerebral edema |  calcium channel |  cacna1a gene |  fatal coma
KOL Index score: 13175

Oral sumatriptan in a dose of 100 mg aborts about 60% of migraine attacks within 2 h, but the headache may recur within 24 h. We investigated: (i) the incidence of headache recurrence after oral sumatriptan (ii) whether a second tablet of sumatriptan at 2 h increases initial efficacy and/or (iii) prevents headache recurrence and (iv) whether a further tablet of sumatriptan treats headache recurrence. In a randomized parallel-group clinical trial, 1246 patients treated one to three ...

Also Ranks for: Headache Recurrence |  oral sumatriptan |  migraine attacks |  dose incidence |  placebo patients
KOL Index score: 13143

Migraine is an episodic neurovascular disorder that is clinically divided into two main subtypes that are based on the absence or presence of an aura: migraine without aura (MO) and migraine with aura (MA). Current molecular genetic insight into the pathophysiology of migraine predominantly comes from studies of a rare monogenic subtype of migraine with aura called familial hemiplegic migraine (FHM). Three FHM genes have been identified, which all encode ion transporters, suggesting that ...

Also Ranks for: Migraine Aura |  molecular genetics |  human pair |  fhm genes |  common forms
KOL Index score: 13114

BACKGROUND: The R192Q mutation of the CACNA1A gene, encoding for the α1 subunit of voltage-gated P/Q Ca2+ channels (Ca(v)2.1), is associated with familial hemiplegic migraine-1. We investigated whether this gain-of-function mutation changed the structure and function of trigeminal neuron P2X3 receptors that are thought to be important contributors to migraine pain.

RESULTS: Using in vitro trigeminal sensory neurons of a mouse genetic model knockin for the CACNA1A R192Q mutation, we ...

Also Ranks for: P2x3 Receptor |  familial hemiplegic |  ganglion neurons |  mice migraine |  trigeminal pain

Key People For Cluster Headache

Top KOLs in the world
Peter ***** *******
cluster headache chronic migraine acute treatment
Arne ***
cluster headache migraine patients chronic pain
Gennaro *******
cluster headache chronic migraine medication overuse
Anish *****
cluster headache brain cancer hemicrania continua
Karl *****
cluster headache basilar artery lifetime prevalence
Gian ******* *******
cluster headache chronic migraine psychiatric comorbidity

Michel Dominique Ferrari:Expert Impact

Concepts for whichMichel Dominique Ferrarihas direct influence:Cluster headache,  Migraine patients,  Migraine attacks,  Familial hemiplegic migraine,  Migraine aura,  Hemiplegic migraine,  Acute treatment,  Subcortical infarcts.

Michel Dominique Ferrari:KOL impact

Concepts related to the work of other authors for whichfor which Michel Dominique Ferrari has influence:Cluster headache,  Migraine patients,  Acute treatment,  Chronic rhinosinusitis,  Nasal polyps,  Psychiatric disorders,  Ischemic stroke.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands | Department of Neurology, Leiden University Medical Center, Leiden, Netherlands | Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands | Dep